Multiple Sclerosis Patients Treated with Diroximel Fumarate in the Real-World Setting have High Rates of Persistence and Adherence

被引：0
|
作者：
Liseno, Jacob [1 ]
Lager, Brittney [1 ]
Miller, Catherine [2 ]
Shankar, Sai L. [2 ]
Mendoza, Jason P. [2 ]
Lewin, James B. [2 ]
机构：
[1] AcariaHealth, Orlando, FL USA
[2] Biogen, Cambridge, MA USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2027
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Assessment of lymphopenia in patients with multiple sclerosis treated with dimethyl fumarate in a real clinical setting
    Alroughani, R.
    Ahmed, S.
    Behbehani, R.
    Al-Hashel, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 593 - 593
  • [22] Assessment of lymphopenia in patients with multiple sclerosis treated with dimethyl fumarate in a real clinical setting
    Alroughani, Raed
    Ahmed, Samar
    Behbehani, Raed
    Al-hashel, Jasem
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP18 - NP18
  • [23] Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
    Rodriguez-Leal, Francisco Alejandro
    Haase, Rocco
    Akguen, Katja
    Eisele, Judith
    Proschmann, Undine
    Schultheiss, Thorsten
    Kern, Raimar
    Ziemssen, Tjalf
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10 : 1 - 11
  • [24] Comparative Effectiveness and Risk of Severe Infection in Adult Patients with Multiple Sclerosis Treated with Diroximel Fumarate versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis
    Obeidat, Ahmed Z.
    Betz, Michelle
    Farber, Rebecca
    Goff, Erica
    Gudesblatt, Mark
    Le Hua
    Mao-Draayer, Yang
    Robertson, Derrick
    Santoro, Jonathan
    Wang, Tony
    Gomes, Daniel
    Bozin, Ivan
    Mendoza, Jason
    Bian, Boyang
    Lewin, Jim
    Belviso, Nicholas
    Shankar, Sai
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1242 - 1243
  • [25] Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity
    Murage, Mwangi J.
    Anderson, Amanda
    Casso, Deborah
    Oliveria, Susan A.
    Ojeh, Clement K.
    Muram, Talia M.
    Merola, Joseph F.
    Zbrozek, Art
    Araujo, Andre B.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (02) : 141 - 149
  • [26] Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
    Hersh, Carrie M.
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Tuly, Rifat
    Gu, Yifan
    Gadkari, Abhijit
    Brown, Brandon
    Shao, Qiujun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [27] TEC-ADHERE: Real-World Persistence and Adherence on Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis in the French OroSEP Patient-Support Program
    Labauge, Pierre
    Creange, Alain
    Moreau, Thibault
    Nouvet-Gire, Jocelyne
    Pedespan, Bernard
    Heinzlef, Olivier
    Texier, Nathalie
    Gros, Marilyn
    Marti, Catherine
    Ruiz, Marta
    Martinez, Mikel
    Castelnovo, Giovanni
    NEUROLOGY AND THERAPY, 2025, 14 (01) : 177 - 192
  • [28] The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
    Wicks P.
    Rasouliyan L.
    Katic B.
    Nafees B.
    Flood E.
    Sasané R.
    BMC Research Notes, 9 (1)
  • [29] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
    Norborg, Hilde
    Riise, Trond
    Myhr, Kjell-Morten
    Grytten, Nina
    Wergeland, Stig
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (02)
  • [30] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
    Norborg, H.
    Riise, T.
    Myhr, K. -M.
    Grytten, N.
    Wergeland, S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 712 - 712
12345